Bicyclic inhibitors of histone deacetylase
Provided herein are compounds and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful in the treatment of conditions associated with inhibition of HDAC (e.g,. HDAC2).
1. A method of treating a condition in a subject selected from Alzheimer's disease, Huntington's disease, fronto-temporal lobar degeneration, Friedreich's ataxia, post-traumatic stress disorder, Parkinson's disease, Parkinson's disease dementia, substance dependence recovery, memory or cognitive function disorder or impairment, neurological disorder with synaptic pathology, disorder of learning distinction, psychiatric disorders, cognitive function or impairment associated with Alzheimer's disease, Lewy body dementia, schizophrenia, Rubinstein Taybi syndrome, Rett Syndrome, Fragile X, multiple sclerosis, age associated memory impairment, age related cognitive decline, and social, cognitive and learning disorders associated with autism, comprising administering to the subject in need thereof an effective amount of a histone deacetylase (HDAC) inhibitor of the Formula:
or a pharmaceutically acceptable salt thereof.
2. A method of treating a condition in a subject selected from Alzheimer's disease, Parkinson's disease, Parkinson's disease dementia, Huntington's disease, and Lewy body dementia, comprising administering to the subject in need thereof an effective amount of a histone deacetylase (HDAC) inhibitor of the Formula:
or a pharmaceutically acceptable salt thereof.